Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
congress
3
×
crispr
3
×
gene editing
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
ethics
fda
gene therapy
glaxosmithkline
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
advaxis
aimmune therapeutics
alder biopharmaceuticals
alector
alexander hardy
alkermes
andrew oxtoby
applied genetics
What
bio
crispr
roundup
american
big
biopharma
biotech
bosley's
bosley’s
bridge
bucks
cas
ceo
coming
congress
congressional
crime
departure
economic
editas
engaging
executives
exit
feud
gene
group
guiding
isn’t
katrine
known
later
lawmakers
left
legal
looming
medical
medicine
month
moves
new
Language
Current search:
congress
×
crispr
×
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@extremetech.com
7 years ago
The gene therapy revolution is coming. Will the US get left behind?
